Sun Pharma to invest $25 million in US biopharmaceutical company Pharmazz Inc
Summary
Sun Pharmaceutical Industries agreed to invest up to $25 million in US biopharmaceutical company Pharmazz Inc. The deal will give Sun Pharma a 22.7% stake on a fully diluted basis after the investment and SAFE conversion. Pharmazz is developing Sovateltide and Centhaquine, both of which already have approvals in India and are moving through global Phase 3 development and US regulatory steps. Sun Pharma also said it may negotiate licensing rights for Sovateltide in certain developed markets, which adds a potential commercialization angle to the investment.
Funding
Amount
$25.0M
Total raised
Date
May 24, 2025
Announcement date
Investors
Sun Pharma
Lead investors
Company
pharmazz.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected